ArticleJournal of Cancer2019

Factors associated with improvement in symptoms and quality of life for first-line EGFR-tyrosine kinase inhibitor treatment in patients with

Yu-Feng Wei et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.